Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Wednesday, Evotec SE (NASDAQ:EVO) reported sales of $201.12 million (182.12 million euros), up from 170.28 million euros reported a year ago.
周三,Evotec SE (纳斯达克:EVO) 报告了销售额为2.0112亿美元(1.8212亿欧元),高于一年前报告的1.7028亿欧元。
The German drug maker reported an EPS loss of 54 cents, down from 8 cents a year ago.
这家德国药品制造商报告了每股亏损54美分,低于一年前的8美分。
Also Read: German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount.
此外,德国药品开发商 Evotec 寻求顾问意见,因收购担忧加剧。
"However, H1 2024 revenues and profitability have been more challenging for the company than expected. We are operating in a more difficult market environment, most notably the slowdown of early-stage R&D spending," said Christian Wojczewski, CEO of Evotec.
Evotec 的 CEO Christian Wojczewski 表示:“然而,2024 上半年的收入和盈利能力比公司预期的更具挑战性。我们正在更加困难的市场环境中运营,尤其是早期研发支出的放缓。”
"This has required us to accelerate our transformation towards sustainable profitable growth, leveraging better on our strengths, driving productivity, reducing complexity, and making the organization stronger for its next growth phase," he added.
他补充说:“这需要我们加速向可持续盈利增长的转型,更好地利用我们的优势,提高生产效率,降低复杂性,并使组织在其下一个增长阶段更加强大。”
The company said the reset for profitable growth is on track to achieve the expected annualized adjusted EBITDA improvement of over 40 million euros starting in the second half of 2024
该公司表示,实现盈利增长的重置计划正在按计划进行,并预计从2024年下半年开始实现超过4.0亿欧元的年化调整后的 EBITDA 改善。
The company has identified a headcount reduction potential of approximately 400 roles (7% of the workforce) across the global footprint and a reduction of the physical footprint by surrendering certain lease agreements.
该公司已确定全球范围内约400个职位(工作人员的7%)存在减员潜力,并通过放弃某些租赁协议来缩减实体占用空间。
The company plans to exit gene therapy and close a site in Orth, Austria. It's also shutting down chemistry activities in Lyon, France, and separating a manufacturing facility in Halle/Westphalia, Germany.
该公司计划退出基因治疗,并关闭奥地利奥斯特的一个站点。同时,该公司还将关闭法国里昂的化学活动,并将德国哈勒/威斯特伐利亚州的一个制造设施分离。
On Tuesday, Evotec announced further progress in its strategic partnership with Bristol Myers Squibb & Co (NYSE:BMY) to build a molecular glue-based pipeline. Performance-based and program-based achievements trigger payments of $75 million to Evotec.
周二,Evotec 宣布其与百时美施贵宝公司 (纽交所:BMY) 的战略合作关系开展取得了进一步进展,以建立一条基于分子粘着剂的流水线。基于绩效和项目的成就将出发支付7500万美元给 Evotec。
Outlook: Evotec expects 2024 revenues of 790 million euros-820 million euros, with adjusted EBITDA of 15 million euros-35 million euros.
展望:Evotec 预计2024年收入为7.9亿欧元-8.2亿欧元,调整后 EBITDA 为1500万欧元-3500万欧元。
Price Action: EVO stock is down 0.60% at $3.30 at last check Wednesday.
截至周三最后一次检查,EVO 股票下跌0.60%,至3.30美元。
- Meta's Threads May Soon Offer Disappearing Posts, Adding Privacy Features: Report.
- Meta's Threads 可能很快提供临时帖子,增加隐私功能:报道。